Quick Answer
Lyell Immunopharma, Inc. reported Total Revenue of $36.0 thousand for fiscal year 2025.
Lyell Immunopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $36.0K -41.0% |
$61.0K -53.1% |
$130.0K -99.8% |
$84.68M +695.1% |
$10.65M +37.3% |
$7.76M +1080.5% |
| Net Income | -$274.45M +20.0% |
-$342.99M -46.2% |
-$234.63M -28.1% |
-$183.12M +26.8% |
-$250.22M -22.4% |
-$204.47M -58.0% |
| Diluted EPS | -$16.06 +38.8% |
-$26.23 -40.3% |
-$18.70 -2427.0% |
-$0.74 +59.8% |
-$1.84 +88.3% |
-$15.69 +34.7% |
| Total Assets | $340.05M -30.7% |
$490.86M -34.6% |
$750.03M -20.0% |
$937.56M -16.8% |
$1.13B +24.1% |
$908.28M |
| Cash and Equivalents | $60.18M -43.0% |
$105.60M -27.5% |
$145.65M +17.9% |
$123.55M -58.0% |
$293.83M +109.3% |
$140.41M +45.2% |
| Stockholders Equity | $248.20M -35.2% |
$382.82M -41.5% |
$654.95M -21.4% |
$833.25M -10.4% |
$929.79M +417.8% |
-$292.53M -163.3% |
| R&D Expense | — | — | $182.94M +14.9% |
$159.19M +14.8% |
$138.69M -23.9% |
$182.24M +186.6% |
| Operating Income | -$269.40M +24.9% |
-$358.75M -45.2% |
-$247.01M -32.0% |
-$187.06M +12.9% |
-$214.78M -1.3% |
-$211.94M -107.6% |
| Shares Outstanding | 21.25M +44.1% |
14.74M -94.2% |
253.96M +1.8% |
249.57M +2.8% |
242.74M +1459.0% |
15.57M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $15.0K | -55.9% | +87.5% |
| Net Income | September 30, 2025 | -$38.85M | +12.9% | +9.0% |
| Diluted EPS | September 30, 2025 | -$2.13 | +38.8% | +26.3% |
| Total Assets | September 30, 2025 | $407.96M | -34.1% | +5.8% |
| Cash and Equivalents | September 30, 2025 | $123.58M | +23.2% | +25.1% |
| Stockholders Equity | September 30, 2025 | $329.12M | -38.0% | +10.1% |
| R&D Expense | September 30, 2025 | $28.17M | -28.7% | -19.2% |
| Operating Income | September 30, 2025 | -$37.25M | +26.2% | +21.0% |
| Shares Outstanding | September 30, 2025 | 19.29M | -92.5% | +30.1% |
- Lyell Immunopharma, Inc. reported Total Revenue of $36.0 thousand for fiscal year 2025.
- Lyell Immunopharma, Inc. showed a decrease of -41.0% in Total Revenue compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Net Income of -$274.45 million for fiscal year 2025.
- Lyell Immunopharma, Inc. showed an increase of +20.0% in Net Income compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Diluted EPS of $16.06 per share (loss) for fiscal year 2025.
- Lyell Immunopharma, Inc. showed an increase of +38.8% in Diluted EPS compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Total Assets of $340.05 million for fiscal year 2025.
- Lyell Immunopharma, Inc. showed a decrease of -30.7% in Total Assets compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Cash and Equivalents of $60.18 million for fiscal year 2025.
- Lyell Immunopharma, Inc. showed a decrease of -43.0% in Cash and Equivalents compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Stockholders Equity of $248.20 million for fiscal year 2025.
- Lyell Immunopharma, Inc. showed a decrease of -35.2% in Stockholders Equity compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported R&D Expense of $182.94 million for fiscal year 2023.
- Lyell Immunopharma, Inc. showed an increase of +14.9% in R&D Expense compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Operating Income of -$269.40 million for fiscal year 2025.
- Lyell Immunopharma, Inc. showed an increase of +24.9% in Operating Income compared to the prior fiscal year.
- Lyell Immunopharma, Inc. reported Shares Outstanding of 21.25 million shares for fiscal year 2025.
- Lyell Immunopharma, Inc. showed an increase of +44.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: